6Hao XP, Willis JE, Pretlow TG, et al. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions [J]. CancerRes, 2000, 60:18-21.
7Moser PL, Kieback DG, Hefler L, et al. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue ilahibitor of metalloproteinase 2 (T1MP-2) in stage IB cervical cancer [J]. Artticartcer Res, 1999, 19:4391 -4393.
8Davidson B, Goldberg I, Kopolovic J, et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization [ J]. Gynecol Oncol, 1999, 73:372 -382.
9Ahmed MI, Salahy EE, Tawfiq H, et al. Matrix metalloproteinase-2, squamous cell carcinoma antigen, and tissue polypeptide-specific antigen expression in Egyptian patients with cervical carcinoma: Relationship with prognosis I J l. Dis Markers, 2004, 20: 333 - 343.
10Shue BC, Len HC, Hoh N, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer [ J ]. Cancer Res, 2003, 63:6537-6542.
